BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the intraoperative MRI equipment market is projected to accelerate at a healthy 7.5% CAGR during the forecast period of 2017 to 2026.

Fact.MR – A Market Research and Competitive Intelligence Provider: Sales in the global back table and cart covers market are slated to grow at above 2.9% CAGR through 2027, opines Fact.MR.

The bio decontamination market has been anticipated to experience innumerable growth opportunities in the upcoming years.

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, announced that the Medicines and Healthcare products Regulatory Agency has awarded LYS-GM101 investigational gene therapy an ‘Innovation Passport’ for the treatment of GM1 gangliosidosis under the United Kingdom’s Innovative Licensing and Access Pathway.

Targovax ASA, a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, announces mOS of 25.0 months for treatment with ONCOS-102 in combination with Standard of Care chemotherapy in malignant pleural mesothelioma in the subgroup of patients receiving therapy in the first-line setting.

BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines, announced the official launch of the BeiGene Bioisland Innovation Center in Guangzhou, China to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations.

McKesson Corporation announced that it has entered into an agreement to sell its Austrian business to Quadrifolia Management GmbH.

BeiGene, Ltd. today announced an option, collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan.

Intra-Cellular Therapies, Inc. today announced that the U.S. Food and Drug Administration approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate.

ObsEva SA today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.